ProfileGDS5678 / 1444711_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 39% 40% 40% 39% 45% 42% 48% 40% 39% 39% 40% 35% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9331239
GSM967853U87-EV human glioblastoma xenograft - Control 22.9035339
GSM967854U87-EV human glioblastoma xenograft - Control 32.9067140
GSM967855U87-EV human glioblastoma xenograft - Control 42.8766240
GSM967856U87-EV human glioblastoma xenograft - Control 52.8467339
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1382545
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0222242
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1300148
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8849640
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8919939
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.88939
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8753540
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8055435
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8946339